{"filing":{"accession_number":"0001654954-26-008321","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"a5437u.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426008321/a5437u.htm"},"events":[{"id":33111,"run_id":30435,"accession_number":"0001654954-26-008321","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This 6-K discloses positive Phase III clinical trial results for Ris-Rez (risvutatug rezetecan), a B7-H3-targeted antibody-drug conjugate in relapsed small cell lung cancer. The ARTEMIS-008 trial met its primary endpoint with a 54% reduction in risk of death versus topotecan (HR 0.46, p\u003c0.0001), representing the first Phase III data demonstrating an OS benefit for a B7-H3 ADC in any tumor type. While this is a significant clinical milestone for GSK's oncology pipeline and would materially affect investor assessment of the company's development prospects, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development milestone that warrants disclosure as an operational event.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36460,"accession_number":"0001654954-26-008321","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This 6-K discloses positive Phase III clinical trial results for Ris-Rez (risvutatug rezetecan), a B7-H3-targeted antibody-drug conjugate in relapsed small cell lung cancer. The ARTEMIS-008 trial met its primary endpoint with a 54% reduction in risk of death versus topotecan (HR 0.46, p\u003c0.0001), representing the first Phase III data demonstrating an OS benefit for a B7-H3 ADC in any tumor type. While this is a significant clinical milestone for GSK's oncology pipeline and would materially affect investor assessment of the company's development prospects, it does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It is a material operational/clinical development milestone that warrants disclosure as an operational event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:25:41.122836+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-14"}]}